The Society for Immunotherapy of Cancer recently published a consensus statement on pembrolizumab for the treatment of SCC of the head and neck, emphasizing that targeting proteins such as PD-1 and PD-L1 have shown promise of durable, long-term survival in responding patients [2]. The gene discussed is CD274; the disease is cancer.